Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Amer M. Zeidan,Jörg Westermann,Tibor Kovacsovics,Sarit Assouline,Andre C. Schuh,Hee-Je Kim,Gabriela Rodriguez Macias,David Sanford,Marlise R. Luskin,Eytan M. Stein,Kamel Malek,Jiaying Lyu,Mario Stegert,Jordi Esteve

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 4|浏览4

暂无评分

摘要

Safety and tolerability of sabatolimab+azacitidine+venetoclax were comparable at 2 dose levels (400 and 800 mg) of sabatolimab and to the safety profile of venetoclax+azacitidine therapy. These findings supported initiation of the expansion cohort of STIMULUS-AML1 at a sabatolimab 800 mg dose.

查看译文

关键词

AML,acute myeloid leukemia,clinical trial,sabatolimab,venetoclax,azacitidine,Phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要